Division of Immunology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan.
Division of Hematology and Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Front Immunol. 2024 Oct 15;15:1444821. doi: 10.3389/fimmu.2024.1444821. eCollection 2024.
PURPOSE: Type I conventional dendritic cells (cDC1s) play a key role in priming anti-tumor cytotoxic T cells and inducing immune tolerance for self-antigens and tumor antigens. However, it remains unclear whether cDC1 has a protective or pathogenic role in multiple myeloma. We investigated a role of cDC1 in myeloma progression. METHODS: A myeloma mouse model was performed by intravenous transplantation of Vk*MYC myeloma cells into XCR1-Diphtheria toxin receptor (DTR) knock-in or wild-type mice. Following injection with Diphtheria toxin (DT), monoclonal (M)-proteins and myeloma cells were analyzed by ELISA and flow cytometry. RESULTS: Here we show that inducible depletion of cDC1 after myeloma transplantation markedly suppressed the progression of myeloma in the bone marrow and extramedullary sites, such as the spleen. cDC1 appeared in the bone marrow and spleen of myeloma-transplanted mice, which highly expressed CD103 and lowly produced interleukin (IL)-12. Consequently, the frequencies of exhausted CD8 T cells and regulatory T cells significantly decreased in the bone marrow of cDC1-depleted mice. CONCLUSIONS: cDC1 supports the progression of myeloma inducing exhausted CD8 T cells and regulatory T cells.
目的:I 型传统树突状细胞(cDC1)在激活抗肿瘤细胞毒性 T 细胞和诱导针对自身抗原和肿瘤抗原的免疫耐受方面发挥关键作用。然而,cDC1 在多发性骨髓瘤中是保护性的还是致病性的尚不清楚。我们研究了 cDC1 在骨髓瘤进展中的作用。
方法:通过静脉注射 Vk*MYC 骨髓瘤细胞到 XCR1-Diphtheria toxin receptor(DTR)敲入或野生型小鼠中建立骨髓瘤小鼠模型。用白喉毒素(DT)处理后,通过 ELISA 和流式细胞术分析单克隆(M)-蛋白和骨髓瘤细胞。
结果:我们发现骨髓瘤移植后诱导性耗尽 cDC1 可显著抑制骨髓和骨髓外部位(如脾脏)骨髓瘤的进展。骨髓瘤移植小鼠的骨髓和脾脏中出现 cDC1,其高表达 CD103 并低产生白细胞介素(IL)-12。因此,耗尽的 CD8 T 细胞和调节性 T 细胞在 cDC1 耗竭小鼠的骨髓中的频率显著降低。
结论:cDC1 支持骨髓瘤的进展,诱导耗尽的 CD8 T 细胞和调节性 T 细胞。
J Immunother Cancer. 2019-4-8
Front Immunol. 2025-4-17
J Microsc Ultrastruct. 2023-1-19
Front Immunol. 2022
Annu Rev Immunol. 2021-4-26
Front Oncol. 2021-2-9
Cancers (Basel). 2021-1-9
Blood. 2020-12-10